H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Dyadic International (DYAI) with a Buy rating and $3 price target The company produces recombinant proteins based on proprietary fungus-based platforms, the analyst tells investors in a research note. The firm is “encouraged” by Dyadic’s efforts to expand its platform into further non-pharmaceutical applications and views them as upside to estimates.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYAI:
- Dyadic International Achieves Milestone Payments and Compliance
- Dyadic International announces achievement of milestone payments
- Dyadic International Amends Security Agreement with CEO Trust
- Craig-Hallum bullish on Dyadic International, initiates with a Buy
- Dyadic International initiated with a Buy at Craig-Hallum